Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families

The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer

A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer

The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905

A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis

MiraKind 6 and 25 percent banner

MiraKind Breast Cancer Awareness

Increased Risk for Second Breast Cancer Study